Korean J Med > Volume 77(1); 2009 > Article
The Korean Journal of Medicine 2009;77(1):1-8.
Recent advance in tailored treatment of gastric cancer
Hei-Cheul Jeung, Sun Young Rha
위암의 맞춤 항암 요법의 최신 지견
정희철, 라선영
Abstract
Even the overall incidence is decreasing and the proportion of early gastric cancer is increasing from the national mass screening program, still gastric cancer is the major issue in Korea. Multimodality approach and the development of novel therapeutic agents enabled us to improve the survival rate of gastric cancer. However, the proper treatment strategy for the subgroups of patients is necessary, which is now categorized based on the clinicopathologic parameters. We need more in-depth information regarding the molecular biology of gastric cancer, and the development of novel targeted biological agents and the biomarkers for the future. Currently, the recent chemotherapeutic agents showed the improved response in advanced gastric cancer. Hence, the basic concept of adjuvant chemotherapy, palliative hemotherapy, neoadjuvant treatment with or without incorporation of radiotherapy become settle down with more evidences from several phase III trials. Especially, after understanding the difference between Asia and Western countries including biology, ethnic difference, operation technology, and the treatment approaches, the qualified, well-designed multinational clinical trials are on-going. Based on the current results, here, I describe the current status of gastric cancer treatment strategy. (Korean J Med 77:1-8, 2009)
Key Words: Gastric cancer; Chemotherapy; Tailored treatment; Biological agent


TOOLS
METRICS Graph View
  • 1,315 View
  • 14 Download

Editorial Office
101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-2271-6791    Fax: +82-2-790-0993    E-mail: kaim@kams.or.kr                

Copyright © 2025 by The Korean Association of Internal Medicine.

Developed in M2PI

Close layer
prev next